| Advances with support vector machines for novel drug discovery VG Maltarollo, T Kronenberger, GZ Espinoza, PR Oliveira, KM Honorio Expert opinion on drug discovery 14 (1), 23-33, 2019 | 86 | 2019 |
| Oxidative stress control by apicomplexan parasites SS Bosch, T Kronenberger, KA Meissner, FM Zimbres, D Stegehake, ... BioMed Research International 2015 (1), 351289, 2015 | 53 | 2015 |
| Small-molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure–activity relationships, antiviral activity, and X-ray structure determination T Pillaiyar, P Flury, N Krüger, H Su, L Schäkel, E Barbosa Da Silva, ... Journal of Medicinal Chemistry 65 (13), 9376-9395, 2022 | 44 | 2022 |
| The application of machine learning techniques to innovative antibacterial discovery and development MSM Serafim, T Kronenberger, PR Oliveira, A Poso, KM Honorio, ... Expert Opinion on Drug Discovery 15 (10), 1165-1180, 2020 | 38 | 2020 |
| ADME profiling in drug discovery and a new path paved on silica A Krüger, V Gonçalves Maltarollo, C Wrenger, T Kronenberger Drug discovery and development-new advances, 1-30, 2019 | 38 | 2019 |
| HQSAR and random forest-based QSAR models for anti-T. vaginalis activities of nitroimidazoles derivatives GC Verissimo, EFM Dutra, ALT Dias, P de Oliveira Fernandes, ... Journal of Molecular Graphics and Modelling 90, 180-191, 2019 | 31 | 2019 |
| LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer R Rudalska, J Harbig, MT Snaebjornsson, S Klotz, S Zwirner, L Taranets, ... Nature cancer 2 (2), 201-217, 2021 | 29 | 2021 |
| Structure-based design of selective salt-inducible kinase inhibitors R Tesch, M Rak, M Raab, LM Berger, T Kronenberger, AC Joerger, ... Journal of Medicinal Chemistry 64 (12), 8142-8160, 2021 | 28 | 2021 |
| The inner rod of virulence‐associated type III secretion systems constitutes a needle adapter of one helical turn that is deeply integrated into the system's export apparatus CE Torres‐Vargas, T Kronenberger, N Roos, T Dietsche, A Poso, ... Molecular microbiology 112 (3), 918-931, 2019 | 28 | 2019 |
| Vitamin B6‐Dependent Enzymes in the Human Malaria Parasite Plasmodium falciparum: A Druggable Target? T Kronenberger, J Lindner, KA Meissner, FM Zimbres, MA Coronado, ... BioMed Research International 2014 (1), 108516, 2014 | 28 | 2014 |
| Molecular modeling applied to nucleic acid-based molecule development A Krüger, FM Zimbres, T Kronenberger, C Wrenger Biomolecules 8 (3), 83, 2018 | 27 | 2018 |
| COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease T Kronenberger, SA Laufer, T Pillaiyar Drug Discovery Today, 103579, 2023 | 25 | 2023 |
| Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease Mpro and Papain-like Protease PLpro of SARS-CoV-2 LH Santos, T Kronenberger, RG Almeida, EB Silva, REO Rocha, ... Journal of Chemical Information and Modeling 62 (24), 6553-6573, 2022 | 24 | 2022 |
| Genomics, epigenomics and pharmacogenomics of familial hypercholesterolemia (FHBGEP): A study protocol JB Borges, VF de Oliveira, GM Ferreira, B Los, TKAA Barbosa, ... Research in social and administrative pharmacy 17 (7), 1347-1355, 2021 | 23 | 2021 |
| Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure–activity relationship analyses T Kronenberger, LR Asse Jr, C Wrenger, GHG Trossini, KM Honorio, ... Future medicinal chemistry 9 (2), 135-151, 2017 | 23 | 2017 |
| Preclinical toxicity of innovative molecules: In vitro, in vivo and metabolism prediction DR Tonholo, VG Maltarollo, T Kronenberger, IR Silva, PO Azevedo, ... Chemico-Biological Interactions 315, 108896, 2020 | 22 | 2020 |
| Advances and challenges in drug design of PPARδ ligands VG Maltarollo, T Kronenberger, B Windshugel, C Wrenger, GHG Trossini, ... Current Drug Targets 19 (2), 144-154, 2018 | 20 | 2018 |
| Antibacterial activity of synthetic 1, 3‐bis (aryloxy) propan‐2‐amines against Gram‐positive bacteria MSM Serafim, SN Lavorato, T Kronenberger, YV Sousa, GP Oliveira, ... Microbiologyopen 8 (11), e814, 2019 | 19 | 2019 |
| Targeting the Plasmodium falciparum plasmepsin V by ligand‐based virtual screening KA Meissner, T Kronenberger, VG Maltarollo, GHG Trossini, C Wrenger Chemical Biology & Drug Design 93 (3), 300-312, 2019 | 19 | 2019 |
| Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles O Burk, M Kuzikov, T Kronenberger, J Jeske, O Keminer, WE Thasler, ... Archives of Toxicology 92, 1435-1451, 2018 | 18 | 2018 |
Antti PosoProfessor of Drug Design, University of Eastern Finland在 uef.fi 的电子邮件经过验证
